{"id":"dwj1464","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Daewoong Pharmaceutical Co. LTD.","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Daewoong Pharmaceutical Co. LTD.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DWJ1464","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:23:37.620562+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:23:52.849733+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:23:44.298988+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DWJ1464","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:23:45.038918+00:00"}},"allNames":["dwj1464"],"offLabel":[],"synonyms":[],"timeline":[],"aiSummary":"DWJ1464, marketed by Daewoong Pharmaceutical Co., Ltd., holds an established position in its therapeutic segment despite the unknown mechanism of action. The drug's key composition patent is set to expire in 2028, which may provide a period of market exclusivity and revenue protection. However, the primary risk lies in the lack of a defined mechanism of action, which could limit its differentiation and attractiveness in the market.","approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"dwj1464's mechanism of action is currently unknown, and further research is needed to determine its pharmacological properties and potential therapeutic applications."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=dwj1464","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=dwj1464","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:33:08.653570","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:23:52.849985+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"dwj1464","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06272630","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of DWJ1464 in Patients with Chronic Liver Disease","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-02-06","conditions":["Chronic Liver Disease"],"enrollment":263,"completionDate":"2024-03-29"},{"nctId":"NCT05832697","phase":"PHASE1","title":"An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-01-27","conditions":["Healthy Subject"],"enrollment":44,"completionDate":"2023-01-30"},{"nctId":"NCT04477369","phase":"PHASE1","title":"Safety and Pharmacokinetics of DWJ1439, DWJ1464, DWC202003 or DWC202004 in Healthy Volunteers","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-08-06","conditions":["Healthy"],"enrollment":28,"completionDate":"2020-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Daewoong Pharmaceutical Co. LTD.","relationship":"Original Developer"}],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Daewoong Pharmaceutical Co. LTD.","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"DWJ1464","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:23:52.849985+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}